Its ability to target ClC-3 channels and MMP-2 in glioblastoma and breast cancer positions it as a promising candidate for further preclinical and clinical evaluation, particularly in the development of tumor-specific diagnostic and therapeutic agents. This evidence concerns the gene CLCN3 and glioblastoma.